SHC Stock Recent News

Sotera Health Company (NASDAQ:SHC ) Q1 2025 Earnings Conference Call May 1, 2025 9:00 AM ET Company Participants Michael Petras - Chairman, Chief Executive Officer Jonathan Lyons - Chief Financial Officer Jason Peterson - Vice President of Investor Relations and Treasurer Conference Call Participants Patrick Donnelly - Citi Brett Fishbin - KeyBanc Matt Sykes - Goldman Sachs Luke Sergott - Barclays Dave Windley - Jefferies Jason Bednar - Piper Sandler Michael Polark - Wolfe Research Operator Good morning. And welcome to the Sotera Health First Quarter of 2025 Earnings Call.

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sotera Health Company (SHC) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago.

CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three months ended March 31, 2025.

CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights.

Investors need to pay close attention to Sotera Health (SHC) stock based on the movements in the options market lately.

Sotera Health offers essential sterilization, lab testing, and advisory services, ensuring safety and regulatory compliance for medical, pharmaceutical, and food products, with high customer retention and long-term contracts. The company operates through Sterigenics, Nordion, and Nelson Labs, with a global network and leading market positions in sterilization services and Co-60 supply. Despite a 6% revenue decline in FY24 due to Nordion's lumpy revenue, Sotera maintains high adjusted EBITDA margins (~50%) and plans for CapEx reduction and debt deleveraging.

Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application

Sotera Health Company (NASDAQ:SHC ) Q4 2024 Earnings Conference Call February 27, 2025 9:00 AM ET Company Participants Jason Peterson – Vice President of Investor Relations and Treasurer Michael Petras – Chairman and Chief Executive Officer Jon Lyons – Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Sean Dodge – RBC Capital Markets Luke Sergott – Barclays Casey Woodring – J.P. Morgan Brett Fishbin – KeyBanc Dave Windley – Jefferies Michael Polark – Wolfe Research Operator Good morning, and welcome to the Sotera Health Fourth Quarter and Full Year 2024 Conference Call.

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.